Chapter 20 — Clinical Implementation of the SIRIAM Platform

The preceding chapters described the scientific foundations, pharmaceutical architecture, ingredient platform and Master Formulae that collectively define the SIRIAM Platform.

The present chapter translates these principles into clinical practice.

Rather than functioning as isolated topical formulations, the Master Formulae are incorporated into a structured clinical workflow that combines anatomical reasoning, neurodermal assessment, regional examination and objective follow-up.

Clinical decision-making within the SIRIAM Platform is based upon four complementary principles:

• identification of the dominant biological region;
• assessment of neurodermal facilitation;
• selection of the appropriate Master Formula;
• longitudinal reassessment using objective and subjective outcome measures.

Every patient follows the same structured sequence.

1. 01Patient Presentation
2. 02Medical History
3. 03Clinical Examination
4. 04Regional Neurodermal Assessment
5. 05SRST Examination
6. 06Surface EMG (when indicated)
7. 07Identification of Dominant System
8. 08Master Formula Selection
9. 09Application Protocol
10. 10Clinical Reassessment
11. 11Maintenance Strategy

Purpose: To identify the dominant biological system before formula selection.

Standard assessment includes:

• Medical History — onset, duration, aggravating factors, relieving factors, previous interventions, medication, trauma, surgery
• Observation — posture, skin colour, swelling, scars, asymmetry, spontaneous guarding
• Palpation — tissue compliance, fascial mobility, skin glide, temperature, tenderness, tissue density
• Functional Assessment — range of motion, resisted movement, neurological examination, provocation tests, movement quality
• Formula selection is never based upon symptoms alone.

Purpose: Identify facilitated spinal segments.

• Principles
• Examination Procedure
• Pressure Standardisation
• Positive Response
• Negative Response
• Grading — Grade 0, Grade 1, Grade 2, Grade 3
• Reliability
• Interpretation
• Limitations

Purpose: Objective quantification of regional muscle activity.

• Discuss: RMS, baseline, contraction, recovery, symmetry, reproducibility
• Clinical indications: baseline, follow-up, treatment comparison, documentation

The clinician determines which regional system predominates.

Examples:

• Upper cervical → OAA DUO
• Respiratory pattern → PHRENIC DUO
• Upper limb → PLEXUS BRACHIALIS
• Upper thorax → CTO DUO
• Epigastrium → PLEXUS SOLARIS
• Thoracolumbar junction → TLO DUO
• Anterior thigh → PLEXUS LUMBALIS
• Posterior thigh → PLEXUS LUMBOSACRALIS
• Pelvic floor → SX DUO
• Diffuse facilitation → KORR
• Biological recovery phase → InflammaSacra Programme

1. 01Clinical Assessment
2. 02Regional Identification
3. 03Primary Formula
4. 04Secondary Formula (if required)
5. 05Application Strategy
6. 06Reassessment

InflammaSacra follows a biological recovery sequence.

1. 01Acute Response
2. 02InflammaSacra I
3. 03Subacute Transition
4. 04InflammaSacra II
5. 05Long-Term Integration
6. 06InflammaSacra III

• Amount applied
• Application frequency
• Massage pressure
• Application direction
• Skin preparation
• Timing
• Regional coverage
• Patient instructions
• Storage
• Treatment duration

Examples:

• Cervical Strategy: OAA → PHRENIC → CTO
• Upper Limb Strategy: PHRENIC → PLEXUS BRACHIALIS
• Thoraco-Abdominal Strategy: CTO → PLEXUS SOLARIS → TLO
• Lumbo-Pelvic Strategy: TLO → PLEXUS LUMBALIS → PLEXUS LUMBOSACRALIS → SX
• Baseline Strategy: KORR → Regional Formula → InflammaSacra (when indicated)

Reassessment includes:

• Clinical symptoms
• Regional palpation
• Skin mobility
• SRST
• Surface EMG
• Photographic documentation (optional)
• Treatment adherence
• Need for formula progression

• Contraindications
• Hypersensitivity
• Open wounds
• Dermatitis
• Pregnancy
• Breastfeeding
• Concurrent medication
• Homeopathic components
• Botanical extracts
• Preservatives
• Patient education

Standardised recording:

• Patient demographics
• History
• Regional findings
• SRST grading
• EMG
• Formula selection
• Application protocol
• Review date
• Outcome

Recommended cases:

• Case 1 — Migraine
• Case 2 — Whiplash
• Case 3 — Thoracic outlet syndrome
• Case 4 — Lateral epicondylalgia
• Case 5 — Post-operative scar
• Case 6 — Lumbar radicular pain
• Case 7 — Piriformis syndrome
• Case 8 — Pelvic pain
• Case 9 — Long COVID
• Case 10 — Parkinson's disease
• Each case should follow the same template: History, Assessment, SRST findings, EMG findings, Formula selection, Treatment sequence, Follow-up, Clinical outcome, Discussion

Recommended outcome measures include:

• Subjective: Visual Analogue Scale (VAS), Numeric Pain Rating Scale (NPRS), Patient-Specific Functional Scale (PSFS), Global Rating of Change (GROC)
• Objective: Surface EMG (RMS and symmetry), SRST grading, Active range of motion, Tissue mobility, Functional performance tests
• Optional: Heart Rate Variability (HRV), Thermography, Ultrasound (research setting)

The SIRIAM Platform does not organise treatment around isolated diagnoses or individual ingredients.

Instead, it applies a systems-based clinical framework in which regional neurodermal biology, structured assessment and phased pharmaceutical support are integrated into a coherent therapeutic strategy.

Clinical implementation therefore combines anatomical reasoning, objective measurement and standardised pharmaceutical application to support physiological tissue homeostasis.

Clinical implementation represents the point at which the pharmaceutical architecture of the SIRIAM Platform is translated into everyday practice. The workflow described in this chapter is intended to promote consistency, reproducibility and transparent clinical reasoning while preserving flexibility for individual patient presentations. By integrating structured assessment, region-specific Master Formulae and phase-based therapeutic systems, the platform aims to provide a standardised yet adaptable framework for neurodermal care. Future refinements should be informed by prospective clinical studies, objective outcome measures and multidisciplinary collaboration.